NCT04616729 (Depo-Trigger) is a Phase 1, PHASE2 clinical trial of Triptorelin 3.75 MG Injection in Breast Cancer Female, sponsored by Universitair Ziekenhuis Brussel.

Who is sponsoring NCT04616729?

NCT04616729 is sponsored by Universitair Ziekenhuis Brussel.

What drugs are being tested in NCT04616729?

Interventions in NCT04616729: Triptorelin 3.75 MG Injection, Transvaginal oocyte retrieval, Triptorelin Injection.

What condition does NCT04616729 study?

NCT04616729 studies Breast Cancer Female.

Is NCT04616729 still recruiting?

NCT04616729 is currently status unknown. Last updated 18 May 2023.

Last reviewed 2023-05-18 · How we verify

NCT04616729: Depo-Trigger

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation

Status unknown Phase 1, PHASE2 Last updated 18 May 2023

What this trial tests

Phase 1, PHASE2 trial testing Triptorelin 3.75 MG Injection in Breast Cancer Female in 30 participants. Status unknown.

Timeline

1 November 2022

Primary endpoint
30 November 2025

31 December 2025

Quick facts

Lead sponsor	Universitair Ziekenhuis Brussel
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 November 2022
Primary completion	30 November 2025
Estimated completion	31 December 2025
Sites	2 locations across Belgium

Drugs / interventions tested

Triptorelin 3.75 MG Injection — full drug profile →
Transvaginal oocyte retrieval
Triptorelin Injection — full drug profile →

Conditions studied

Breast Cancer Female — all drugs for Breast Cancer Female →

Sponsor

Universitair Ziekenhuis Brussel — full company profile →

Who can join

Adults 18 to 35, female only, with Breast Cancer Female. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

For breast cancer patients who are candidates to receive chemotherapy, concurrent use of temporary ovarian suppression with gonadotropin-releasing hormone agonists (GnRHa) can be offered as ovarian protection. Because ovarian stimulation for oocyte cryopreservation is usually performed using a GnRH antagonist protocol and typically involves final oocyte maturation triggering with a GnRH agonist, the investigators designed this study to explore the feasibility of combining the final oocyte maturation trigger and the start of ovarian suppression. Short-term cotreatment with GnRH antagonists is needed to induce rapid luteolysis (in view of prevention of ovarian hyperstimulation). To demonstrate the safety of GnRH agonist depot triggering followed by daily GnRH antagonist luteolysis, this pilot study is set out to analyse the endocrine profile and ovarian morphology of this novel protocol.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Breast Cancer Female

Currently open trials in the same condition.

NCT07505797 — ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) · recruiting
NCT07198724 — ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrin · Phase 1, PHASE2 · recruiting
NCT07331506 — Validation of the Oncoliq Test for the Early Detection of Breast Cancer. · recruiting
NCT07214883 — UCF MammoChat: Image Repository · recruiting
NCT07120100 — Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Surviv · NA · recruiting

Other Universitair Ziekenhuis Brussel trials

Trials by the same sponsor.

NCT07536230 — Deep Learning Framework for Continuous Depth of Anesthesia Forecasting · not yet recruiting
NCT07533968 — The Aim of This Study is to Gain Insight Into the Occurrence of Irritable Bowel Symptoms During Ovarian Stimulation in I · NA · not yet recruiting
NCT07289984 — Correlation Between Diagnostic Nerve Block Response and Cryoneurolysis Outcome in Chronic Musculoskeletal Disorders and · NA · not yet recruiting
NCT06923813 — Assessment of Nutrient Absorption in Enterally Fed Post-intensive Care Unit Patients Using Bomb Calorimetry: do the Calo · NA · recruiting
NCT07401004 — Effect of Blink-Based Training on Cancer Detection in Colorectal Polyp Images by Medical Students/Non GI-trainees · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04616729 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universitair Ziekenhuis Brussel
Last refreshed: 18 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04616729.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing